News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer
Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Sunitha Lakshminarayanan, as Chief Technology Officer, effective today.
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection
February 20, 2024 Press Release Cefepime-Taniborbactam Superior to Meropenem for the Composite Efficacy Endpoint Composite Efficacy Sustained at Late Follow-up Visit Safety Profile Consistent with...
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID
December 5, 2023 Publication reaffirms the proven efficacy and safety of rezafungin dosed once-weekly versus a current standard of care echinocandin dosed once-daily PARSIPPANY, NJ,
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.
November 9, 2023 Press Release Parsippany, N.J., and Malvern, PA -- November 9, 2023 — Melinta Therapeutics LLC (“Melinta”) and Venatorx Pharmaceuticals, Inc. (“Venatorx”), today announced that